Elias Dakwar
Associate Professor of Psychiatry at Columbia University
Data updated
Research Footprint
Elias Dakwar appears in 6 tracked papers (2014–2020), most studied alongside Ketamine and Placebo, across Substance Use Disorders (SUD), Depressive Disorders and Safety & Risk Management.
Most-cited paper: A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial (176 citations).
Frequent co-authors: Edward Nunes, Carl Hart and Frances Levin.
Background & Research
Elias Dakwar, MD, is an addiction psychiatrist and researcher at Columbia University whose work focuses on novel treatments for cocaine, alcohol, and other substance use disorders. His studies have examined ketamine combined with psychotherapy and mindfulness, as well as the role of psychedelic-like experiences in clinical response.
Key Impact
He is a leading clinical researcher on ketamine-assisted treatment for substance use disorders, with influential randomized trials exploring how ketamine’s psychoactive effects may contribute to therapeutic outcomes.
Collaboration Network
4 collaborators· click a node to visit their profile
Full network →Affiliations
Institutions, companies, and organisations Elias Dakwar is associated with.
Columbia University
academicResearch with psychedelics has been taking place at Columbia University in New York since 2014. Researchers from various departments at the university including Medicine, Psychology and Psychiatry have conducted numerous trials investigating the effects ketamine has on substance use disorders. Some research exploring the anti-depressant effects of ketamine has also taken place. More recently, Columbia University served as a test site for COMPASS Pathway's COMP360 trial which explored the effects of psilocybin on treatment-resistant depression. Professor of Clinical Psychiatry, Dr David Hellerstein served as the principal investigator at this study site.
View stakeholder →University of Toronto
University of Toronto is a leading Canadian research university whose psychedelic and psychiatric research spans the Department of Psychiatry, University Health Network collaborations, and specialized clinical units including mood-disorders psychopharmacology programs.
View stakeholder →New York State Psychiatric Institute
State-funded psychiatric research institute affiliated with Columbia University, located in New York City. A key site for psilocybin clinical trials including the landmark COMP360 study for treatment-resistant depression, and conducts broader research on LSD, DMT, ayahuasca, and ketamine through Columbia's Depression Evaluation Service.
View stakeholder →CUIMC
Columbia University Irving Medical Center (CUIMC) is a major academic medical centre in New York City, integrating Columbia University's Vagelos College of Physicians and Surgeons with NewYork-Presbyterian Hospital and conducting research across neuroscience, psychiatry, and translational medicine. CUIMC serves as the primary clinical site for the Ketamine Biomarker Validation trial (NCT07307768), an EEG-based Phase I study examining dose-response relationships across three ketamine infusion levels in adults with treatment-resistant major depressive disorder.
View stakeholder →